Since the SMN2 copy number is the primary genetic modifier of disease severity, several therapeutic approaches for SMA have focused on increasing expression of SMN through modulation of SMN2 exon 7 splicing [4,5,6]. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.